title: Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients.
abstract: Nine hospitalized schizophrenic patients with tardive dyskinesia were treated with the calcium-channel antagonist verapamil under single-blind conditions. The tardive dyskinesia and activation scores decreased, and the anxiety/depression scores increased. The changes were small but statistically significant.
authors.affiliation: Psychiatry Service, New York Veterans Administration Medical Center, NY 10010.
authors.forename: S
authors.initials: S
authors.lastname: Reiter
authors.forename: L
authors.initials: L
authors.lastname: Adler
authors.forename: B
authors.initials: B
authors.lastname: Angrist
authors.forename: E
authors.initials: E
authors.lastname: Peselow
authors.forename: J
authors.initials: J
authors.lastname: Rotrosen
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects; D001008:Anxiety Disorders / Q000523:psychology; D003866:Depressive Disorder / Q000523:psychology; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D014700:Verapamil / Q000627:therapeutic use*
chemical_list: D014150:Antipsychotic Agents; D014700:Verapamil